logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Liraglutide for weight management in obese adolescents aged 12-17 years old

< Back

Liraglutide for weight management in obese adolescents aged 12-17 years old

Drugs

Endocrine, Nutritional and Metabolic

April 2019


Liraglutide is in development for weight management in obese adolescents aged 12-17 years old. Obesity is defined as abnormal or excessive fat accumulation that may impair health. Obesity is associated with an increased risk of a number of common causes of disease and death including diabetes, cardiovascular disease, and some cancers. For individuals classified as obese, the risk of poor health increases sharply with increasing Body Mass Index (BMI). The BMI is used to determine a person’s weight in regard to their height as underweight, of normal weight, overweight or obese. Preventing and managing obesity is a complex problem, and it is unlikely that obesity can be addressed through primary care management alone.
Liraglutide acts like a hormone the body produces naturally that regulates appetite, known as glucagon-like-peptide (GLP-1). By activating areas of the brain that regulate appetite, liraglutide may decrease feelings of hunger which can lead to lower calorie intake and weight loss. If licensed, liraglutide may improve long-term outcomes for weight management in obese adolescents 12-17 years old who currently have limited treatment options.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts